Review Article
The Prognostic Value of Nanog Overexpression in Lung Cancer: A Meta-Analysis
Table 1
Characteristics of studies included in the meta-analysis.
| First author
-year | Patient
source | Study
design | Number of patients
Total (P/N) | Method | Antibody | Cut-off | Follow-up
(months) | HR estimation | HR (95% CI)
(OS) | Survival | Study quality (NOS) |
| | Chiou-2010 | China | R | 118 (78/40) | IHC | CST | Position | 80 | Sur-curve | 1.47 (1.01-2.12) | OS | 7 | | Li-2013 | China | R | 309 (94/215) | IHC | CST | 5% | 69.5 | HR | 1.70 (1.25-2.32) | OS | 8 | | Du-2013 | China | R | 123 (98/25) | IHC | CST | Score 8 | 60 | Sur-curve | 5.48 (1.42-21.12) | OS | 7 | | Luo (1)-2013 | China | R | 62 (30/32) | IHC | CST | Position | 60 | HR | 2.11 (1.08-4.11) | OS | 6 | | Luo (2)-2013 | China | R | 106 (26/80) | IHC | CST | 25% | 60 | Sur-curve | 1.23 (0.85-1.79) | OS | 6 | | Mo-2014 | China | R | 50 (36/14) | IHC | CST | Position | No data | No data | No data | No data | 6 | | Sodja -2015 | Slovenia | R | 50 (25/25) | RT-PCR | | median | 32.5 | HR | 1.30 (0.70-2.39) | OS, DFS | 6 | | Park-2016 | Korea | R | 226 (96/130) | IHC | Epitomics | Grade 2 | 125 | HR | 1.70 (1.05–2.76) | OS, DFS | 8 | | Yao-2016 | China | R | 156 (129/27) | IHC | Proteintech | 10% | 25 | HR | 1.86 (1.02-3.36) | OS | 6 | | Chang-2017 | Korea | R | 112 (44/68) | IHC | CST | Position | 65 | HR | 3.00 (1.98–4.54) | OS, DFS | 8 | | Lee-2017 | Korea | R | 110 (55/55) | IHC | CST | Position | 65 | HR | 2.89 (2.18-4.62) | OS, DFS | 7 |
|
|
R, retrospective; P, positive; N, negative; IHC, immunohistochemistry; HR, hazard ratios; CI, confidence interval; OS, overall survival; DFS, disease free survival; NOS, Newcastle-Ottawa-Scale.
|
